June 21, 2025
2 min watch
CHICAGO — On this video, Paolo F. Caimi, MD, MBA, employees doctor at Cleveland Clinic, discusses KITE-363, an anti-CD19/CD20 chimeric antigen receptor T-cell remedy, being studied for sufferers with relapsed/refractory B-cell lymphoma.
Security and preliminary efficacy outcomes of an open-label, multicenter part 1 research of KITE-363 (Kite, Gilead Sciences) have been introduced at ASCO Annual Assembly.
Reference:
- Dahiya S, et al. Summary 7003. Offered at: ASCO Annual Assembly; Could 30-June 3, 2025; Chicago.
Revealed by:
Sources/Disclosures
Collapse
Supply:
Caimi PF, et al. Strengthening the strike: Novel remedy approaches in relapsed-refractory giant B-cell lymphoma. Offered at: ASCO Annual Assembly; Could 30-June 3, 2025; Chicago.
Disclosures:
Caimi reviews no related monetary disclosures.
